CLDN18.2-Targeted CAR-T Cell Therapy (CT041) in Subjects with Cancers of the Digestive System

Time: 12:30 pm


  • Claudin18.2 (CLDN18.2) has highly expressed in gastric, pancreatic and other GI cancers
  • CT041 were well tolerated in subjects with CLDN18.2- positive digestive system cancers and delivers high response rate and sustained remission in the previously treated subjects with gastric cancer
  • CycloCAR technology to co-express IL7+CCL21 may improve the efficacy and allogeneic THANK-uCAR technology could reduce costs and increase affordability in cancer